Tom Holdich

1.9k total citations
25 papers, 489 citations indexed

About

Tom Holdich is a scholar working on Oncology, Immunology and Infectious Diseases. According to data from OpenAlex, Tom Holdich has authored 25 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Immunology and 5 papers in Infectious Diseases. Recurrent topics in Tom Holdich's work include CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and HIV/AIDS drug development and treatment (5 papers). Tom Holdich is often cited by papers focused on CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and HIV/AIDS drug development and treatment (5 papers). Tom Holdich collaborates with scholars based in United States, United Kingdom and Canada. Tom Holdich's co-authors include Birgit Huber, Piyush M. Patel, L. DuBuske, J. Sawyer, Paul K. Keith, John Posner, Friedrich Horak, PE Rolan, Werner Aberer and Anthony J. Frew and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Tom Holdich

25 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Holdich United States 9 161 129 97 90 80 25 489
Anna Vila Spain 8 177 1.1× 29 0.2× 23 0.2× 112 1.2× 28 0.3× 25 363
Bhavna Kantesaria United States 16 72 0.4× 150 1.2× 15 0.2× 31 0.3× 461 5.8× 28 930
Karin Frutig Switzerland 11 27 0.2× 109 0.8× 13 0.1× 97 1.1× 72 0.9× 12 623
Matt Noble United Kingdom 12 10 0.1× 72 0.6× 67 0.7× 41 0.5× 81 1.0× 34 450
F Scheiffarth Germany 11 44 0.3× 43 0.3× 21 0.2× 31 0.3× 15 0.2× 176 598
F. Javier Vilar United Kingdom 12 15 0.1× 91 0.7× 20 0.2× 22 0.2× 156 1.9× 20 623
Hiroshi Umemura Japan 14 14 0.1× 44 0.3× 38 0.4× 15 0.2× 29 0.4× 40 565
Misty Saracino United States 15 5 0.0× 64 0.5× 28 0.3× 31 0.3× 109 1.4× 23 729
J. Maares Switzerland 12 168 1.0× 11 0.1× 20 0.2× 424 4.7× 117 1.5× 14 653
Qihong Zhao United States 10 12 0.1× 119 0.9× 20 0.2× 24 0.3× 104 1.3× 21 792

Countries citing papers authored by Tom Holdich

Since Specialization
Citations

This map shows the geographic impact of Tom Holdich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Holdich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Holdich more than expected).

Fields of papers citing papers by Tom Holdich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Holdich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Holdich. The network helps show where Tom Holdich may publish in the future.

Co-authorship network of co-authors of Tom Holdich

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Holdich. A scholar is included among the top collaborators of Tom Holdich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Holdich. Tom Holdich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tine, Brian A. Van, Marcus O. Butler, Dejka M. Araujo, et al.. (2019). ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma. Annals of Oncology. 30. v684–v685. 20 indexed citations
2.
Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology. 29. viii731–viii731. 2 indexed citations
3.
Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. Journal of Clinical Oncology. 36(15_suppl). 3056–3056. 8 indexed citations
4.
5.
6.
Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043). Annals of Oncology. 27. vi368–vi368. 2 indexed citations
7.
Mackall, Crystal L., Sandra P. D’Angelo, Mihaela Cristea, et al.. (2016). Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.. Journal of Clinical Oncology. 34(15_suppl). 3040–3040. 6 indexed citations
8.
Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS3101–TPS3101. 3 indexed citations
9.
Merchant, Melinda S., Mihaela Cristea, Edward A. Stadtmauer, et al.. (2015). Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.. Journal of Clinical Oncology. 33(15_suppl). TPS3102–TPS3102. 5 indexed citations
10.
Patel, Piyush M., et al.. (2013). Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. Journal of Allergy and Clinical Immunology. 133(1). 121–129.e2. 70 indexed citations
11.
DuBuske, L., Anthony J. Frew, Friedrich Horak, et al.. (2011). Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy and Asthma Proceedings. 32(3). 239–247. 90 indexed citations
12.
DuBuske, L., Anthony J. Frew, Friedrich Horak, et al.. (2011). Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy and Asthma Proceedings. 32(6). 466–466. 9 indexed citations
13.
DuBuske, L., M. Castells, & Tom Holdich. (2009). Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy. Journal of Allergy and Clinical Immunology. 123(2). S216–S216. 4 indexed citations
14.
Holdich, Tom & J. Sawyer. (2008). Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor. Expert Opinion on Pharmacotherapy. 9(12). 2021–2025. 3 indexed citations
15.
Cahn, Pedro, et al.. (2008). Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection. Clinical Drug Investigation. 28(2). 129–138. 3 indexed citations
16.
Holdich, Tom, et al.. (2007). Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 51(8). 2943–2947. 23 indexed citations
17.
Holdich, Tom, et al.. (2006). Pharmacokinetics of Single Oral Doses of Apricitabine, a Novel Deoxycytidine Analogue Reverse Transcriptase Inhibitor, in Healthy Volunteers. Clinical Drug Investigation. 26(5). 279–286. 12 indexed citations
18.
Weatherley, B.C., et al.. (1995). Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers. Antimicrobial Agents and Chemotherapy. 39(1). 20–27. 7 indexed citations
19.
Rolan, PE, et al.. (1994). Examination of some factors responsible for a food‐induced increase in absorption of atovaquone.. British Journal of Clinical Pharmacology. 37(1). 13–20. 92 indexed citations
20.
Hudson, Alan T., Maurice Dickins, Colin D. Ginger, et al.. (1991). 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.. PubMed. 17(9). 427–35. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Vila Breakdown of academic impact, for papers by Bhavna Kantesaria Breakdown of academic impact, for papers by Karin Frutig Breakdown of academic impact, for papers by Matt Noble Breakdown of academic impact, for papers by F Scheiffarth Breakdown of academic impact, for papers by F. Javier Vilar Breakdown of academic impact, for papers by Hiroshi Umemura Breakdown of academic impact, for papers by Misty Saracino Breakdown of academic impact, for papers by J. Maares Breakdown of academic impact, for papers by Qihong Zhao
Rankless by CCL
2026